Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07601243 · ClinicalTrials.gov registry record · Phase 1
Study of GS-2426 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 174
- Enrollment target
NCT07601243: Recruiting Phase 1 study, sponsored by Gilead Sciences.
NCT07601243 is a Phase 1 study that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 174 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (190% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07601243, a Phase 1 study, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 174 participants
- Enrollment target
Study Summary
The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors. The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in participants with MTAP-deleted advanced solid tumors and to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended phase II dose (RP2D).
Interventions
- DRUG GS-2426
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2026-06-02 |
| Est. Completion | 2029-01 |
| Phase | Phase 1 |
What NCT07601243 shows while recruiting
NCT07601243 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (190% higher).
The record links to 0 conditions, and to 1 intervention - of which GS-2426 is the first listed.
NCT07601243 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07601243 about?
NCT07601243 is a clinical study titled "Study of GS-2426 in Participants With Advanced Solid Tumors". The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors. The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in p...
What is the current status of trial NCT07601243?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2026-06-02. Estimated completion is 2029-01.
What interventions are being tested in trial NCT07601243?
The interventions under investigation include: GS-2426 (DRUG).
Who is sponsoring clinical trial NCT07601243?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07601243's enrollment target sits among peer trials
174 322nd of 2000 higher than 1,677 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI